The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
